RxDoctor Payments Data

Daniel Jipescu, DO

Internal Medicine · Fort Worth, TXNPI 1134573637

Payments from drug & device makers

$26,774in general payments, 2019–2025

Across 379 payments — averaging $70.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$6K
  • Penumbra, Inc.$3K
  • Boston Scientific$3K
  • Abbott$2K
  • Philips North America LLC$2K
  • Abiomed$2K
  • plus $8K from 37 others
$56in research payments, 2019–2025

Across 1 payment — averaging $55.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$56

What the payments were for

  • Travel & lodging$7,00726%
  • Food & beverage$19,36172%
  • Education$4052%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,774 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$327,582
Medicare patients
413
Services billed
2,660

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban102$96,238
EntrestoSacubitril/Valsartan44$35,018
XareltoRivaroxaban24$18,660
Repatha SureclickEvolocumab22$18,108
OzempicSemaglutide15$13,698
JardianceEmpagliflozin13$9,413
BrilintaTicagrelor17$7,986
Ranolazine ErRanolazine73$5,675
VascepaIcosapent Ethyl11$4,386
ClopidogrelClopidogrel Bisulfate125$1,879
Metoprolol Succinate100$1,504
Isosorbide Dinitrate58$1,371
Potassium Chloride59$698
Valsartan13$686
Atorvastatin Calcium81$674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$202$96,238102 claims
NovartisEntresto$171$35,01844 claims
Johnson & JohnsonXarelto$86$18,66024 claims
Novo NordiskOzempic$372$13,69815 claims
Boehringer IngelheimJardiance$44$9,41313 claims
AstraZenecaBrilinta$834$7,98617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →